These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2205787)

  • 1. Future medical prospects for Sandostatin.
    Harris AG
    Metabolism; 1990 Sep; 39(9 Suppl 2):180-5. PubMed ID: 2205787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future medical prospects for Sandostatin.
    Harris AG
    Z Gastroenterol; 1990 Sep; 28 Suppl 2():55-60. PubMed ID: 1980778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical use of somatostatin analogues in the treatment of cancer.
    Lamberts SW; Krenning EP; Klijn JG; Reubi JC
    Baillieres Clin Endocrinol Metab; 1990 Mar; 4(1):29-49. PubMed ID: 1975166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report.
    Saif MW
    JOP; 2011 Jul; 12(4):425-8. PubMed ID: 21737909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide, a new somatostatin analogue.
    Katz MD; Erstad BL
    Clin Pharm; 1989 Apr; 8(4):255-73. PubMed ID: 2653711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Somatostatin analog (octreotide) in clinical use: current and potential indications].
    Meier R; Dierdorf R; Gyr K
    Schweiz Med Wochenschr; 1992 Jun; 122(25):957-68. PubMed ID: 1621078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].
    Stöckmann F; Creutzfeldt W
    Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical use of octreotide (Sandostatin) in endocrinology].
    Prelević GM
    Med Pregl; 1993; 46(9-10):343-8. PubMed ID: 7997211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
    Ben Yosef R; Glaser B; Catane R
    Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
    Arnold R; Frank M; Kajdan U
    Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
    Öberg K; Lamberts SW
    Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of endocrine and nonendocrine secretory diarrheal states with Sandostatin.
    Gaginella TS; O'Dorisio TM; Fassler JE; Mekhjian HS
    Metabolism; 1990 Sep; 39(9 Suppl 2):172-5. PubMed ID: 2205786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.
    Lamberts SW; Bakker WH; Reubi JC; Krenning EP
    Metabolism; 1990 Sep; 39(9 Suppl 2):152-5. PubMed ID: 2169572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
    Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW
    Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
    Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
    J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly.
    de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ
    Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
    Arnold R; Neuhaus C; Trautmann ME
    Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
    [No Abstract]   [Full Text] [Related]  

  • 19. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
    Battershill PE; Clissold SP
    Drugs; 1989 Nov; 38(5):658-702. PubMed ID: 2689136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sandostatin on neuroendocrine tumours of the gastrointestinal system.
    Buchanan KD
    Recent Results Cancer Res; 1993; 129():45-55. PubMed ID: 8394596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.